Testicular germ cell tumors are among the most curable metastatic solid tumors, largely because of the success of cisplatin-based chemotherapy. However, patients with poor-risk disease remain a challenging subgroup, with approximately one-third still dying from their cancer despite modern treatment.
These patients may present with high tumor burden, markedly elevated tumor markers, mediastinal primary tumors, nonpulmonary visceral metastases, or brain metastases. Their management requires more than frontline chemotherapy alone, including careful treatment selection, postchemotherapy surgery, salvage strategies, toxicity management, and long-term survivorship care.
For this reason, the review emphasizes the importance of multidisciplinary care and referral to experienced centers to improve outcomes in this complex population. The article was published in the ASCO Educational Book, Volume 46, Issue 3, on May 14, 2026.
Title: How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer
Authors: Noah Richardson, MD; Alok K. Tewari, MD, PhD; Patrizia Giannatempo, MD; Michael F. Basin, MD; Amedeo Nuzzo, MD; Federica Mascaro, MD; Darren R. Feldman, MD; Nabil Adra, MD; and Siamak Daneshmand, MD.
Understanding Poor-Risk Germ Cell Tumors
The review explains that current risk stratification for advanced germ cell tumors is based on the International Germ Cell Cancer Collaborative Group (IGCCCG) classification system. Poor-risk disease is defined in patients with nonseminomatous histology who present with a mediastinal primary tumor, nonpulmonary visceral metastases, or markedly elevated tumor markers, including AFP greater than 10,000 ng/mL, hCG greater than 50,000 mIU/mL, or LDH greater than 10 times the upper limit of normal. Any one of these marker elevations is sufficient to define poor-risk disease.
Contemporary outcomes have improved compared with historical cohorts. The IGCCCG Update Consortium reported a 5-year progression-free survival of 54% and overall survival of 67% among poor-risk patients treated with frontline cisplatin-etoposide–based chemotherapy.
Still, prognosis remains poor for many patients, particularly those with brain metastases, mediastinal primary disease, increasing age, and nonpulmonary visceral involvement.
Read more about Testicular Cancer on OncoDaily.
Choosing the Right First Treatment
Four cycles of cisplatin-based triple-drug chemotherapy remain the standard first-line treatment for poor-risk germ cell tumors. The established regimens are BEP, which includes bleomycin, etoposide, and cisplatin, or VIP, which includes etoposide, ifosfamide, and cisplatin.
Both regimens have shown comparable efficacy, although VIP is associated with greater hematologic and other toxicities. The review notes that these approaches are expected to cure approximately 50%–60% of poor-risk patients in the frontline setting. Maintaining full-dose treatment on schedule is important, and granulocyte-colony stimulating factor support may be used to preserve dose intensity.
Treatment selection depends on patient and disease characteristics. Bleomycin should generally be avoided in patients with extensive pulmonary metastases, significant pulmonary disease, age over 50 years, or notable renal impairment. VIP may also be favored in patients with primary mediastinal nonseminomatous germ cell tumors because of concerns about pulmonary toxicity after bleomycin exposure.
Reading Tumor Markers Carefully
Tumor marker kinetics are an important part of treatment monitoring. Patients with very high hCG levels are expected to have a decline of approximately one logarithmic unit per cycle during the first two cycles of chemotherapy. An unfavorable decline is associated with worse prognosis.
However, the review cautions that clinicians should not automatically change curative-intent therapy just because hCG remains detectable at the end of chemotherapy, if the marker is still declining and there is no confirmed radiographic progression. In one retrospective analysis of patients presenting with hCG above 50,000 mIU/mL, more than half remained continuously disease-free after frontline chemotherapy, even though fewer than 10% had normalized their hCG by the start of the fourth cycle.
Importantly, nearly half of patients whose hCG remained elevated more than one month after completing chemotherapy eventually normalized their levels and remained continuously disease-free. For patients with declining but still detectable hCG at the end of treatment, close weekly monitoring is recommended before initiating salvage therapy, unless there is a confirmed rise in tumor markers or radiographic progression.
When Urgent Treatment Comes First
Some poor-risk patients present with extensive metastatic disease requiring urgent treatment before orchiectomy or biopsy. In selected patients with a testicular mass and elevated AFP or hCG, treatment may begin immediately if disease is threatening organ function. The review describes a “course 0” approach using a 3- to 5-day regimen of standard-dose etoposide and cisplatin for stabilization before definitive curative-intent therapy.
Patients with metastatic choriocarcinoma may be at risk for serious bleeding after chemotherapy initiation, including pulmonary hemorrhage or bleeding from brain metastases. These situations require rapid multidisciplinary management and careful treatment sequencing.
Read More About Men’s Health on OncoDaily
The Role of Surgery After Chemotherapy
After frontline chemotherapy, all known metastatic sites should be reassessed with imaging. CT remains the most commonly used modality, while MRI is increasingly used to reduce radiation exposure. FDG-PET is not indicated in nonseminoma and is not recommended for residual seminoma masses smaller than 3 cm.
Surgery remains essential for many patients with residual disease. In nonseminomatous germ cell tumors, postchemotherapy retroperitoneal lymph node dissection may reveal necrosis, teratoma, or viable carcinoma. The review reports that resected masses contain necrosis in 40%–50%, teratoma in 35%–40%, and viable carcinoma in 10%–15% of cases.
Postchemotherapy surgery is technically demanding and should be performed by experienced teams. These procedures may require vascular reconstruction, nephrectomy, or other adjunctive operations, particularly in patients with bulky residual disease.
The review also emphasizes that multifocal residual disease can be difficult to manage because pathology may vary between sites. For this reason, surgical resection of residual masses remains an important part of treatment planning, especially in nonseminomatous disease with normalized tumor markers.
Managing Residual Disease and Teratoma
Growing teratoma syndrome is another important clinical scenario. It is suspected when metastatic masses enlarge during chemotherapy while tumor markers normalize. Because teratoma is resistant to chemotherapy and radiation, complete surgical resection is required.
The review notes that incomplete resection is associated with recurrence rates of 83%, compared with 4%–9% after complete resection. This reinforces the need for complete removal of all disease sites whenever feasible.
Late relapse, defined as relapse more than 2 years after initial treatment, is often chemotherapy-resistant and may contain teratoma or somatic-type malignancy. When disease is resectable, surgery remains the preferred approach.
Desperation Surgery: A Last Resort That Can Still Cure
For patients whose disease continues to progress despite multiple lines of chemotherapy, desperation surgery remains a meaningful option in carefully selected cases. The review defines desperation surgery as resection of nonresponsive or progressive disease with rising tumor markers, typically after exhausting systemic treatment options.
While the overall prognosis in this setting is poor, complete surgical resection can still achieve long-term disease control. Studies have found that long-term survival ranges between 30% and 70% in patients who undergo complete resection, with better outcomes associated with limited extent of disease, lower prior IGCCCG risk stage, and the absence of rising tumor markers leading up to surgery. Critically, patients who are not candidates for complete resection should not undergo desperation surgery, as incomplete removal of disease is associated with worse outcomes rather than benefit.
What Happens After Relapse
Although many patients are cured with first-line therapy, up to 30% experience relapse and require salvage treatment. Current salvage strategies include conventional-dose chemotherapy and high-dose chemotherapy followed by autologous stem cell transplantation.
The most widely used conventional-dose regimens include TIP, which combines paclitaxel, ifosfamide, and cisplatin, and VeIP, which combines vinblastine, ifosfamide, and cisplatin. TIP has demonstrated durable efficacy, with complete response rates of 63% and 10-year progression-free and overall survival of 62% and 66%, respectively.
High-dose chemotherapy approaches include tandem carboplatin and etoposide regimens, as well as TI-CE, which incorporates paclitaxel and ifosfamide before sequential high-dose carboplatin and etoposide. These strategies require specialized expertise because of significant toxicity and the need for transplant support. A recent meta-analysis reported treatment-related mortality of 3% with conventional-dose chemotherapy compared with 7.5% with high-dose chemotherapy, which is an important consideration in patient selection.
The review highlights that the ongoing TIGER trial may help clarify the optimal first-salvage approach. Until stronger prospective comparative data are available, patient selection remains guided by clinical risk factors, disease behavior, and treatment-center expertise.
Read about Lance Armstrong and Testicular Cancer on OncoDaily.
Brain Metastases in Poor-Risk Disease
Brain metastases are rare in the overall germ cell tumor population but occur more frequently in poor-risk disease. They are most often seen in nonseminomatous tumors and are associated with increased morbidity and mortality.
The prognosis of brain metastases in germ cell tumors differs significantly depending on whether they are present at diagnosis or develop later at relapse. According to the largest retrospective study on this topic, the Global Germ Cell Tumor Group series of 523 patients, outcomes in these two groups are strikingly different.
Patients with brain metastases present at diagnosis had a 3-year overall survival of 48% and a median overall survival of 29.5 months. By contrast, patients who developed brain metastases at relapse fared considerably worse, with a 3-year overall survival of only 27% and a median overall survival of just 8 months. In both groups, the presence of multiple brain metastases and concurrent liver or bone involvement were associated with worse outcomes.
The review notes that brain imaging should be performed in any patient with neurologic symptoms. In asymptomatic patients, imaging may also be considered in selected poor-risk cases, particularly those with tumor marker elevations such as hCG above 5,000 or AFP above 10,000, extensive lung metastases, nonpulmonary visceral disease, or choriocarcinoma-predominant histology.
Treatment depends on whether brain metastases are present at diagnosis or develop at relapse. Patients with synchronous brain metastases are generally treated with chemotherapy for poor-risk disease, while symptomatic lesions may require surgery or radiotherapy before systemic treatment. For metachronous brain metastases, multimodality treatment is often considered, including focal therapy and systemic salvage treatment.
Life After Cure
Because many patients with poor-risk germ cell tumors can still be cured, survivorship care is essential. The treatment burden is high, and long-term toxicities may include secondary malignancies, cardiovascular disease, peripheral neuropathy, metabolic dysfunction, renal impairment, hearing loss, hypogonadism, infertility, fatigue, and reduced bone mineral density.
Fertility preservation should be discussed before treatment whenever possible, as both chemotherapy and surgery may affect future fertility. Long-term surveillance is also important because late relapse can occur years after treatment, and annual tumor marker monitoring may help detect recurrence.
Final Takeaway
Poor-risk testicular germ cell tumors remain curable, but they require highly specialized care. The review emphasizes that optimal outcomes depend on appropriate first-line chemotherapy, careful interpretation of tumor marker response, expert postchemotherapy surgery, individualized salvage therapy, and long-term survivorship management.
The central message is clear: patients with poor-risk disease should be managed through multidisciplinary collaboration and, whenever possible, referred to experienced centers. Continued clinical trial participation and collaborative research remain essential to improve cure rates for this rare but complex patient population.
The full article is available on the ASCO Educational Book.
You Can Watch More on OncoDaily Youtube TV.